The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond
Background: Oligometastatic disease has emerged as a possibly distinct metastatic phenotype in numerous cancer histologies. With the advancement in treatment modalities including stereotactic body radiation therapy (SBRT), certain patients may derive benefits from local ablative therapy. SBRT alone...
Main Authors: | Benjamin E. Onderdonk, Steven J. Chmura |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00706/full |
Similar Items
-
The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field
by: Mihailo Miljanic, et al.
Published: (2022-09-01) -
Quaternary and beyond cytoreduction: An updated and expanded analysis
by: Beryl L. Manning-Geist, et al.
Published: (2021-08-01) -
Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After
by: Susan Woody, et al.
Published: (2022-05-01) -
Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
by: Joanna Jiang, et al.
Published: (2022-12-01) -
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
by: Gregor Habl, et al.
Published: (2017-05-01)